Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Claritin Does Not Infringe Schering Patent - Appeals Court

This article was originally published in The Tan Sheet

Executive Summary

The Aug. 1 decision by a Washington D.C. federal appeals court finding certain loratadine patent claims invalid "does not preclude patent protection for metabolites of known drugs," the judges write
Advertisement

Related Content

Claritin Litigation Rehearing Denial Could Affect New Drug Patents
Claritin Litigation Rehearing Denial Could Affect New Drug Patents
Claritin Litigation Rehearing Denial Could Affect New Drug Patents
Leiner ships loratadine
Leiner ships loratadine
Leiner ships loratadine
Desloratadine Production Not Anticipated In Loratadine Patent – Schering
Desloratadine Patent Claims No Bar To Generic Claritin, Judge Says
Desloratadine Patent Claims No Bar To Generic Claritin, Judge Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS095765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel